HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 342 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... February 12, 2020 Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... August 14, 2023 In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in... March 10, 2026 Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas... January 26, 2026 Load more HOT NEWS Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each... Study Reinforces Treatment Idea for Cancer with Microsatellite Instability Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched... New Research in Treating Lymphoma and Improving Equity in Cancer Clinical...
